Protein dynamics is essential to understand protein function and stability, even though is rarely investigated as the origin of loss-of-function due to genetic variations. Here, we use biochemical, biophysical, cell and computational biology tools to study two loss-of-function and cancer-associated polymorphisms (p.R139W and p.P187S) in human NAD(P)H quinone oxidoreductase 1 (NQO1), a FAD-dependent enzyme which activates cancer pro-drugs and stabilizes several oncosuppressors. We show that p.P187S strongly destabilizes the NQO1 dimer in vitro and increases the flexibility of the C-terminal domain, while a combination of FAD and the inhibitor dicoumarol overcome these alterations. Additionally, changes in global stability due to polymorphisms and ligand binding are linked to the dynamics of the dimer interface, whereas the low activity and affinity for FAD in p.P187S is caused by increased fluctuations at the FAD binding site. Importantly, NQO1 steady-state protein levels in cell cultures correlate primarily with the dynamics of the C-terminal domain, supporting a directional preference in NQO1 proteasomal degradation and the use of ligands binding to this domain to stabilize p.P187S in vivo. In conclusion, protein dynamics are fundamental to understanding loss-of-function in p.P187S, and to develop new pharmacological therapies to rescue this function.The study of NAD(P)H quinone oxidoreductase 1 (NQO1, EC 1.6.5.2) polymorphisms is particularly interesting due to its enhanced expression in several types of cancer 1-3 . NQO1 is a dimeric, two-domain FAD-dependent enzyme (Fig. 1A) which catalyses the two electron reduction of quinones and related substrates through an enzyme-substituted mechanism in which NAD(P)H enters the active site, reduces the FAD and exits as the oxidised form, allowing the subsequent substrate binding and reduction by the FADH 2 4 . Primarily, NQO1 avoids the formation of reactive semiquinones, maintains antioxidants such as α -tocopherol and ubiquinone in their reduced state, and also activates some anticancer bioreductive drugs (e.g. mitomycin C (MMC) and a MMC analogue, EO9) 4,5 . Additionally, NQO1 interacts with tumour suppressors such as p53 and p73 and stabilizes them towards proteasomal degradation 6-9 , while its interaction with the 20S proteasome prevents the degradation of a plethora of proteins with intrinsically disordered regions, including several cell cycle regulators, tumor suppressors and apoptotic proteins 10 .